Fredun Medhora, Managing Director 

Fredun Pharmaceuticals, a leading pharma formulation manufacturing company, reported that its net profit in the March quarter was up 56 per cent at Rs 11 crore on the back of good demand.

Income increased 27 per cent to ₹213 crore y-on-y while EBITDA was up 67 per cent at ₹29 crore.

The company has declared a dividend of ₹0.70 per share.

The board has also recommended issuance of bonus shares in the ratio of 2 fully paid-up equity shares for every 1 existing shareholders/warrant holders.

In FY’26, net profit was up 60 per cent at Rs 33 crore as income jumped 40 per cent to ₹639 crore. EBITDA registered a growth of 72 per çent to ₹95 crore.

Profitability has been accelerating faster than revenue, indicating improving business quality, said the company.

Fredun Medhora, Managing Director said the company’s growth was driven across segments, with continued strength in generics complemented by increasing traction in nutraceuticals, cosmeceuticals and pet care.

The balanced mix is helping the company scale more sustainably and reduce dependence on any single segment, he said.

The company has started investing in the next phase of growth with the launch of the premium hormone therapy range and the DAULCÉL platform, he said.

It marks the company’s entry into more specialized, wellness and preventive healthcare segments, he added.

Alongside this, the expansion of the Palghar facility and the upgrade in our credit rating will give the capacity and financial strength to support future growth, said Medhora.

The company will continue to focus on building presence across segments while gradually increasing the share of differentiated and higher value products, he added.

Published on May 25, 2026